Literature DB >> 21315712

Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.

Margarita T Murri-Plesko1, Alzbeta Hulikova, Egbert Oosterwijk, Andrew M Scott, Anna Zortea, Adrian L Harris, Gerd Ritter, Lloyd Old, Stefan Bauer, Pawel Swietach, Christoph Renner.   

Abstract

Carbonic anhydrase IX (CAIX) is a hypoxia-induced, membrane-tethered enzyme that is highly expressed in many cancers. It catalyses the hydration of CO(2) to HCO(3)(-) and H(+), and the reverse dehydration reaction. Recent studies have shown an important role for CAIX in pH regulation and it has been speculated that CAIX may play a role in supporting cancer progression towards more aggressive forms of the disease. Clinical correlative studies in many tumours have shown that high expression is related to poor outcome. In the present study, we have selected antigen-binding antibody fragments (Fab) against human CAIX by phage-display, and tested these for inhibitory potency on CAIX catalytic activity. Inhibition was assessed from the kinetics of the CAIX-catalysed reaction, using assays performed on intact cells over-expressing CAIX, and their CAIX-containing membrane fragments. Inhibition was also assessed in multi-cellular tissue-models (spheroids) from the kinetics of CO(2) venting. We have identified a Fab antibody, labelled MSC8, and its corresponding full-length IgG that inhibited CAIX by up to 57% and 76%, respectively, with half-maximal inhibition at 0.3μg/ml. Incubation of CAIX-expressing cells with MSC8 IgG produced a lasting inhibitory effect. The inhibitory effect was prompt and was also observed in isolated membrane-fragments, suggesting that a direct inhibitory interaction takes place between the antibody and CAIX. The inhibitory effects in spheroids argue for a physiological relevance of the antibody. Biologically-active antibodies against CAIX can be used as selective, high-affinity inhibitors in experimental studies to dissect the role of CAIX and, possibly, therapeutically by targeting a catalytically-active cancer-related protein.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315712     DOI: 10.1016/j.ejphar.2011.01.063

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  20 in total

1.  Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.

Authors:  Tania Fiaschi; Elisa Giannoni; Maria Letizia Taddei; Paolo Cirri; Alberto Marini; Gianfranco Pintus; Cristina Nativi; Barbara Richichi; Andrea Scozzafava; Fabrizio Carta; Eugenio Torre; Claudiu T Supuran; Paola Chiarugi
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

2.  Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII.

Authors:  Mam Y Mboge; Robert McKenna; Susan C Frost
Journal:  Top Anticancer Res       Date:  2015

3.  Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents.

Authors:  Mikhail Krasavin; Stanislav Kalinin; Tatiana Sharonova; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 4.  Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases.

Authors:  Narges K Tafreshi; Mark C Lloyd; Marilyn M Bui; Robert J Gillies; David L Morse
Journal:  Subcell Biochem       Date:  2014

5.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

6.  Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.

Authors:  Paolo E Porporato; Suveera Dhup; Rajesh K Dadhich; Tamara Copetti; Pierre Sonveaux
Journal:  Front Pharmacol       Date:  2011-08-25       Impact factor: 5.810

Review 7.  Recent developments in targeting carbonic anhydrase IX for cancer therapeutics.

Authors:  Paul C McDonald; Jean-Yves Winum; Claudiu T Supuran; Shoukat Dedhar
Journal:  Oncotarget       Date:  2012-01

8.  Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.

Authors:  De-Kuan Chang; Raymond J Moniz; Zhongyao Xu; Jiusong Sun; Sabina Signoretti; Quan Zhu; Wayne A Marasco
Journal:  Mol Cancer       Date:  2015-06-11       Impact factor: 27.401

Review 9.  Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers.

Authors:  G Ilardi; N Zambrano; F Merolla; M Siano; S Varricchio; M Vecchione; G De Rosa; M Mascolo; S Staibano
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 10.  Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma.

Authors:  Jeannette C Oosterwijk-Wakka; Otto C Boerman; Peter F A Mulders; Egbert Oosterwijk
Journal:  Int J Mol Sci       Date:  2013-05-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.